Why is Roche continuing to study emugrobart for weight loss?

Roche believes the scientific rationale for using emugrobart to promote muscle growth during weight loss is strong, as individuals with obesity have higher levels of myostatin which the drug blocks.

What neuromuscular disorders was emugrobart being studied for?

Emugrobart was being studied for spinal muscular atrophy and facioscapulohumeral muscular dystrophy.

When are the initial results expected for the emugrobart study with Zepbound?

Initial results from the 48-week study combining emugrobart and Eli Lilly's Zepbound are expected this year.

Home / Health / Roche: Muscle Drug for Weight Loss Lives On

Roche: Muscle Drug for Weight Loss Lives On

20 Mar

•

Summary

Roche continues studying emugrobart for muscle growth during weight loss.
Work on emugrobart for neuromuscular disorders is halted due to ineffectiveness.
Emugrobart aims to block myostatin, a protein restricting muscle growth.

Roche: Muscle Drug for Weight Loss Lives On

Roche Holding AG is shifting its research focus for the experimental compound emugrobart. While the company has ceased development for neuromuscular disorders like spinal muscular atrophy and facioscapulohumeral muscular dystrophy due to ineffectiveness, it plans to continue studying the drug's potential for aiding muscle growth during weight loss. This strategic pivot aims to differentiate Roche in the competitive obesity market.

The scientific basis for emugrobart's use in obesity is considered robust by Roche. The company highlights that individuals with obesity do not suffer from nerve or muscle-wasting conditions and possess higher levels of myostatin, a protein that emugrobart is designed to inhibit. This makes the compound a promising candidate for preserving muscle mass.

Emugrobart is currently being evaluated in a 48-week study in conjunction with Eli Lilly & Co.'s Zepbound, a blockbuster obesity medication. Initial results from this study are expected to be released this year. Separately, a study in FSHD showed increased myostatin levels, but failed to demonstrate muscle growth benefits after 52 weeks of treatment.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.